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A Rare Case of Prednimustine-Induced Myoclonus
Prednimustine is frequently used in the treatment of chronic lymphocytic leukemia, non-Hodgkin's lymphoma, Hodgkin's disease, and ovarian and breast cancers. However, care should be taken to recognize early neurologic side effects that may have disabling consequences.
We report here a rare neurologic side effect associated with administration of prednimustine. A 79-year-old woman presented with weight loss, night sweats, asthenia, bilateral inguinal lymphadenopathy, and splenomegaly. She had had a 19-year history of lowgrade follicular lymphoma, which had been treated 8 years previously by various chemotherapy regimens, including prednimustine.
A biopsy of an inguinal adenopathy disclosed Hodgkin's disease, histologically different from the previously known lymphoma. She was treated with an oral combination of lomustine at a dose of 80 mg/m 2 on day 1 and etoposide at a dose of 100 mg/m 2 and prednimustine at a dose of 60 mg/m 2 , both given on days 1 to 5 (corresponding to a total dose of chlorambucil of 6 mg/kg), and she was premedicated with allopurinol and ondansetron. On day 3, she noticed abnormal jerks of her hands, which increased during the subsequent days and finally involved the four limbs. On day 6, unable to stand, she fell and broke her right arm. Neurologic assessment at the emergency room disclosed severe myoclonia of the four limbs. Her mental state and conscious state were normal, and laboratory tests showed no electrolyte abnormalities. Clonazepam was introduced, and the myoclonia gradually decreased and disappeared on day 8. A medical history revealed that the patient had experienced the same hand jerks 8 years before while taking prednimustine. We replaced prednimustine with prednisone in subsequent treatment cycles, and the myoclonus did not reappear.
Prednimustine is an ester of prednisolone and chlorambucil. Elimination of chlorambucil and its metabolite phenylacetic mustard is prolonged after oral administration of prednimustine compared with chlorambucil alone. Neurotoxicity was dose limiting in a phase I trial of high-dose chlorambucil (1), and chlorambucil-related myoclonus has been described (2) in a 71-year-old woman treated for a lymphocytic lymphoma with a 5-day regimen of chlorambucil and deltacortisone. In this patient, the jerks appeared on day 3, culminated on day 7, and disappeared gradually after another week.
Three cases of prednimustine-induced myoclonus have also been reported (3) in women previously treated with cisplatin for an ovarian cancer. The myoclonia developed on day 4 during a 5-day regimen of prednimustine (120 mg/m 2 per day) and disappeared after cessation of the chemotherapy and administration of diazepam. Hypomagnesemia found in these three patients was considered a possible contributing factor.
The mechanism of chlorambucilinduced myoclonus is not known. Myoclonus arises from the central nervous system in a complex interaction between brain stem, cortex, and cerebellum. It is found in several neurologic diseases, including mitochondrial myopathies with central nervous system dysfunction, in which deficiencies of components of the respiratory chain are observed (4) . Similarly, the neurotoxicity of an alkylating agent (5) The presence of cells in the blood stream of prostate cancer patients that stain positively for both prostatespecific antigen (PSA) and for the monocyte marker CD14 seems to indicate a low risk of metastasis formation. This cellular biomarker might be helpful in the assessment of the prognosis for prostate cancer patients with organ-restricted disease. It could be used to define a subgroup of patients with a low risk of life-threatening bone metastasis, although these patients show evidence of circulating prostate cancer cells by flow cytometry (1) or PSA-PCR2 (2).
We describe here 16 patients with N0M0 stage prostate cancer and 11 patients with prostate cancer with bone metastasis (stage M1) as well as two control groups (eight patients with bladder cancer and nine patients with benign prostatic hyperplasia). So that we could determine the number of PSA/ CD14-double-stained cells in the peripheral blood of the patients by flow cytometry, 10 mL of EDTA-treated blood was drawn from the patients by venipuncture, and the erythrocytes were depleted by density-gradient centrifugation. The cells were stained simultaneously with anti-PSA-fluorescein isothiocyanate (FITC) (Coulter-Immunotech, Hamburg, Federal Republic of Germany) and an antibody labeled with CD14-phycoerythrin (PE) (Dianova, Hamburg). Controls for nonspecific binding of the antibody, negative controls with blood from healthy women, and positive controls with LNCaP cells were performed. The PSA-positive and PSA/CD14-double-positive cells were counted by a count gate discrimination procedure adjusted to the exclusion of nonspecific, stained cells in the FL1 (FITC)/FL2 (PE) plot of the negative control; two million peripheral white blood cells were analyzed for each sample after erythrocyte depletion.
The data in Fig. 1 suggest that the exclusive detection of molecular signals, either by immunologic means or by polymerase chain reaction, representing PSA-positive cells in the circulation, is not sufficient to estimate the risk of metastasis in prostate cancer.
We are entering a new period of research on circulating cancer cells. 
